- Conditions
- Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 2,010
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rhabdomyosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more
- Conditions
- Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Paroxysmal Nocturnal Hemoglobinuria, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Relapsing Chronic Myelogenous Leukemia, Thrombocytopenia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- bryostatin 1, sargramostim, laboratory biomarker analysis, pharmacological study
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hemarthrosis, Hemophilia
- Interventions
- Intra articular PRP Injection
- Biological
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 34
- States / cities
- Buena Park, California • Duarte, California • Irvine, California + 27 more
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride, Hydroxychloroquine, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Biological · Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
- Interventions
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, filgrastim, laboratory biomarker analysis
- Biological · Radiation · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- immunoenzyme technique, laboratory biomarker analysis, medical chart review
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cetuximab, cisplatin, irinotecan hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
- Biological · Drug · Other + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, FDG-Positron Emission Tomography, Glofitamab, Ibrutinib, Magnetic Resonance Imaging, Obinutuzumab
- Procedure · Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Eosinophilia, Dyspepsia
- Interventions
- Not listed
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 2,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 14
- States / cities
- La Jolla, California • Los Angeles, California • Miami, Florida + 9 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- ALT-803, Nivolumab
- Biological
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Weston, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 1 more
- Conditions
- Obesity, Overweight
- Interventions
- LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
- Interventions
- Atezolizumab, Biopsy, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, External Beam Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pemetrexed, Positron Emission Tomography, Therapeutic Conventional Surgery
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 46
- States / cities
- Jonesboro, Arkansas • Tampa, Florida • Boise, Idaho + 41 more
- Conditions
- Leukemia
- Interventions
- gene expression analysis, molecular genetic technique, polymorphism analysis, protein expression analysis, diagnostic laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Fort Wayne, Indiana
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells, cyclophosphamide, sargramostim, laboratory biomarker analysis
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Carboplatin, Etoposide, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
- Interventions
- Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Duarte, California